Barriers in Parkinson’s Disease
Reading Time: 3 minutes
Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder that targets dopamine-producing neurons in the brain’s substantia nigra and basal ganglia, leading to a spectrum of motor and nonmotor symptoms. A growing …
Read MoreNews Takeaway: Semaglutide’s Potential Role in Alzheimer’s Prevention – A Closer Look
Reading Time: 2 minutes
SummarySemaglutide, commonly prescribed for diabetes and obesity, is now showing promise in potentially lowering Alzheimer’s risk. Recent findings, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, suggest …
Targeting Alpha-Synuclein in Parkinson’s
Reading Time: 4 minutes
Introduction
Recent research has unveiled promising strategies to treat Parkinson’s disease (PD), focusing on targeting alpha-synuclein clumping and its transmission between brain cells. Understanding the role of cell surface proteins like …
Read MorePromising GLP-1 Drugs for Parkinson’s and Alzheimer’s
Reading Time: 3 minutes
Introduction
In recent years, a class of diabetes drugs, known as GLP-1 receptor agonists, has shown significant potential in treating not just diabetes but also neurodegenerative conditions like Parkinson’s disease (PD) …
Read MoreContinuous Infusion Therapy for Parkinson’s: A New Solution
Reading Time: 3 minutes
Introduction
Managing motor fluctuations in advanced Parkinson’s disease (PD) is an ongoing challenge, particularly as oral medications lose efficacy over time. The recent approval of Vyalev by the FDA offers new …
Read More